BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4687 related articles for article (PubMed ID: 6378389)

  • 1. Production of C3 as a marker of lymphokine-mediated macrophage activation.
    Koestler TP; Kirsh R; Kline T; Rieman D; Greig R; Poste G
    Cell Immunol; 1984 Aug; 87(1):1-14. PubMed ID: 6378389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.
    Poste G; Kirsh R; Fogler WE; Fidler IJ
    Cancer Res; 1979 Mar; 39(3):881-92. PubMed ID: 427777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.
    Celada A; Gray PW; Rinderknecht E; Schreiber RD
    J Exp Med; 1984 Jul; 160(1):55-74. PubMed ID: 6330272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF).
    De Groot JW; De Weger RA; Vandebriel RJ; Den Otter W
    Immunobiology; 1989 Jun; 179(2-3):131-44. PubMed ID: 2676851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes.
    Fidler IJ; Raz A; Fogler WE; Hoyer LC; Poste G
    Cancer Res; 1981 Feb; 41(2):495-504. PubMed ID: 7004633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of murine macrophages. I. Different pattern of activation by poly I:C than by lymphokine or LPS.
    Taramelli D; Varesio L
    J Immunol; 1981 Jul; 127(1):58-63. PubMed ID: 6787132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of macrophage activation and tumor cell cytolysis by cyclosporin-A.
    Wright B; Greig R; Poste G
    Biochem Biophys Res Commun; 1984 Sep; 123(2):710-5. PubMed ID: 6435619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
    Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T
    J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of macrophage complement receptor function in vitro. IV. The lymphokine that activates macrophage C3 receptors for phagocytosis binds to a fucose-bearing glycoprotein on the macrophage plasma membrane.
    Griffin FM; Mullinax PJ
    J Exp Med; 1984 Oct; 160(4):1206-18. PubMed ID: 6384418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
    Fidler IJ; Schroit AJ
    J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities.
    Kelso A; Glasebrook AL; Kanagawa O; Brunner KT
    J Immunol; 1982 Aug; 129(2):550-6. PubMed ID: 7045227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.
    Sone S; Poste G; Fidler IJ
    J Immunol; 1980 May; 124(5):2197-202. PubMed ID: 7365253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular activation of human and rodent macrophages by human lymphokines encapsulated in liposomes.
    Kleinerman ES; Fogler WE; Fidler IJ
    J Leukoc Biol; 1985 May; 37(5):571-84. PubMed ID: 3920339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
    Sone S; Fidler IJ
    J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages.
    Poste G; Kirsh R
    Cancer Res; 1979 Jul; 39(7 Pt 1):2582-90. PubMed ID: 87267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between murine macrophage Fc receptor-mediated phagocytic function and competency for activation for non-specific tumor cytotoxicity.
    Leu RW; Rummage JA; Rahimi MB; Herriott MJ
    Immunobiology; 1986 Apr; 171(3):220-33. PubMed ID: 3519439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon.
    Sadlik JR; Hoyer M; Leyko MA; Horvat R; Parmely M; Whitacre C; Zwilling B; Rinehart JJ
    Cancer Res; 1985 May; 45(5):1940-5. PubMed ID: 3921233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.
    Kleinerman ES; Schroit AJ; Fogler WE; Fidler IJ
    J Clin Invest; 1983 Jul; 72(1):304-15. PubMed ID: 6348087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity.
    Kern DE; Grabstein KH; Okuno K; Schreiber RD; Greenberg PD
    J Immunol; 1989 Dec; 143(12):4308-16. PubMed ID: 2687379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of various inhibitors of arachidonic acid oxygenation on macrophage superoxide release and tumoricidal activity.
    Schultz RM; Nanda SK; Altom MG
    J Immunol; 1985 Sep; 135(3):2040-4. PubMed ID: 2991375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 235.